PIPE-791 in Idiopathic Pulmonary Fibrosis (IPF)
EU CTIS ID: 2025-521901-42-00
What this study is testing
To investigate the efficacy of PIPE-791 compared to placebo based on the change from baseline in forced vital capacity (FVC).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Male or female ≥ 40 years of age at the time of Randomization • A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP. • Percent predicted (pp) FVC ≥ 40% on Screening spirometry • Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy, approved for the treatment of IPF (nintedanib or pirfenidone, but not both concurrently)
You likely can't join if
- • Those with a history of interstitial lung disease (ILD) other than IPF are not eligible. • Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible. • Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible. • Those with an estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) (Inker 2021) or who have Child-Pugh Class B or C hepatic impairment are not eligible. • Female participants must not be of childbearing potential. Additional inclusion and exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Belgium
- Denmark
- Greece
- Germany
- France
- Portugal
- Poland
- Spain
- Mexico
- Chile
- Peru
- Taiwan
- Canada
- New Zealand
- Argentina
- Japan
- Korea, Republic of
- Serbia
- Brazil
- Australia
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Belgium; Denmark; Greece; Germany; France; Portugal and 18 more locations. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.